Skip to content

Evaluation of the Liposomal trivalent antimony on cutaneous leishmaniasis treatment

Pilot evaluation of the treatment of cutaneous leishmaniasis using liposomal trivalent antimony as a complementary topical treatment (A RCT study)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250202064600N1
Enrollment
202
Registered
2026-01-05
Start date
2026-03-21
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention Group: This group will receive liposomal trivalent antimony drops three times daily for wound treatment over a duration of six months. The medication regimen may be adjust

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Duration of the lesion is less than 3 months Number of lesions is between a minimum of 2 and a maximum of 5 lesions Wound size is less than or equal to 30 millimeters in one diameter Volunteer participation in the study and signing of the consent form

Exclusion criteria

Exclusion criteria: Pregnancy Breast feeding Infants Applying an alternative treatment method during therapy Presence of a serious or severe underlying condition, such as cardiovascular, renal, or hepatic disease, confirmed by clinical examination and laboratory investigations Leishmanial lesion on the face, Urogenital, and perianal regions Drug or substance addiction Use of immunosuppressive drugs or corticosteroids Alcohol abuse

Design outcomes

Primary

MeasureTime frame
Complete Clinical Cure. Timepoint: Measurement of the diameter of lesions in the days 30,60, and 90. Method of measurement: Measurement of the number and diameter of lesions.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Zarean

Mashhad University of Medical Sciences

Zareanm@mums.ac.ir+98 51 3800 2404

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026